SGLT2 inhibitorrelated adverse effects, including genital mycotic infections, volume depletion, and rarely ketoacidosis, remain clinically relevant and should be considered when these agents are prescribed as part of combination therapy and importantly, the intrinsic risk of hypoglycemia with combined GLP-1 receptor agonist and SGLT2 inhibitor therapy is low because neither class directly stimulates insulin secretion in a glucose-independent manner and when hypoglycemia occurs, it is more commonly related to concomitant insulin or sulfonylurea use rather than the combination itself [41, 42, 44]
Eli Lilly has announced a number of new U.S
This creates a challenging bottleneck for formulators who need to deliver a functional dose to achieve the desired output
Both approaches have valid applications depending on the research context
In 2023, branded obesity drug sales reached $6 billion, and this figure is expected to grow exponentially as demand continues to rise and these medications are used to treat a broader range of diseases
Nielsen MJ, Rasmussen MR, Andersen CB, Nexo E, Moestrup SK